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Abstract
Semisolid systems (creams, gels etc.) for dermal application 
get more and more importance in pharmaceutical and cosmetic 
industry. However the number of methodologies for their phy-
sico-chemical characterization have been increasing; deve-
lopment of methods for the measurement of the active agent’s 
release onto the skin surface is still a challenging task. 
Beside measuring the amount of the active agent reaching the 
skin; dissolution testing (also called release testing) can be also 
a good indicator of product composition changes, therefore it 
can be used as quality control methodology. 
The purpose of this study was to investigate the in vitro drug 
release of active agents from hydrogels, organogels, o/w and 
w/o creams, emulgels and w/o/w multiple emulsions for der-
mal use by means of the vertical diffusion cell methodology, for 
quality control purposes.
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1 Introduction
Dissolution studies are developed and are available mainly 
for solid dosage forms (tablets, capsules); different methodolo-
gies validated for these forms are detailed in the main Pharma-
copoeias [1,2]. There is no compulsory method in any Pharma-
copoeia for semisolid dosage forms; only two guidelines are 
available suggesting equipment for the measurement of drug 
release from these preparations. According to these guidelines 
and also based on literature data, drug release has been exten-
sively investigated by means of the Franz cell diffusion system 
with a synthetic membrane [3-6].
The experimental conditions in drug release testing such as 
receptor phases, membrane-types, usage of different animal 
skin-models etc. depend on the purpose of the experiments; 
whether the aim is quality control or so called bioavailability 
testing in order to decrease the number of animal testing or 
eliminating them [7,8].
Concerning cosmetic products, the product behavior on the 
skin and also the release of the active agent content should be 
tested under in vitro conditions without animals; as the EU 
banned cosmetic testing on animals in 2009, therefore alterna-
tives should be found for evaluation [9].
The following figure summarizes the role of drug release 
studies in case of semisolid dermal preparations (Figure 1.).
Predicting the practical applicability or changes within a 
given system with mathematical modelling [10,11] or different 
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experimental methods – such as this drug release/dissolution 
measurements has increasing importance nowadays. As seen 
on the Figure 1.; active agent release from a cosmetic or phar-
maceutical product is an important quality indicator when 
(1) describing a given composition; (2) it’s necessary to detect 
the effect of changes in components and manufacturing pro-
cess; and (3) we have to follow up the changes during storage 
(stability testing). It can be also used as bioavailability testing 
in order to predict the „in vivo” performance of the developed 
product.
2 Aim
The aim of this study is to evaluate the applicability of drug 
release testing in following the composition changes in case 
of 17 cosmetic and pharmaceutical dosage forms. The in vitro 
drug release data in case of two active agents were measured 
from different vehicles (hydrogel, organogel, w/o and o/w 
creams, o/w emulgels and w/o/w multiple emulsions) for der-
mal use. The presented compositions were developed by our 
research group earlier [12,13].
3 Experiments
3.1 Compositions of the investigated products
The drug release process of 1.0 w/w% diclofenac sodium 
from different products (n=15) and 1.0 w/w% ketamine HCl 
containing systems (n=2) was measured through synthetic 
cellulose acetate membrane soaked in the receiving medium 
(Table 1, Table 2).
3.2 Drug release measurements 
The Franz vertical diffusion cell system (Hanson Research 
Co.) containing 6 cells, and equipped with autosampler (Han-
son Microette Autosampling System) was used for the drug 
release measurements. 
The products were placed on the synthetic cellulose acetate 
membrane (Porafil, Macherey-Nagel, Germany) with pore size 
of 0.45 μm. The diffusion area was 1.767 cm2. Experiments 
run at 32±0.5°C and 25±0.5°C (in case of w/o/w). 800 μl sam-
ples were taken after 0.5,1,2,3,4,5,6 hours. Phosphate buffer 
(pH 5.4±0.1) was chosen for receptor medium. Absorbance was 
measured by UV spectrophotometer (Unicam Helios α UV-Vis 
Spectrophotometer, England) at 275 nm and 269 nm (w/o/w). 
The blank agents without active agents served as references in 
the analytical method.
4 Results and discussion
The release profiles of hydrogels and w/o creams are illust-
rated in Figures 2-4.
Very low amount of active agent was released even after 
6 hours of experiments in case of hydrogels and w/o creams. 
The difference in release rates between the 0.8 and 0.9 w/w% 
polymers containing products wasn’t significant. A slightly 
increased amount was released in case of 1 w/w% polymer con-
tent, which phenomena is due to the increased trietanolamine 
content, facilitating the diclofenac dissolution through the 
membrane.
Drug release from w/o creams is mainly driven by the diffu-
sion capacity of the active agent through the compositions with 
slightly different viscosities (Figure 3.). No significant diffe-
rences were found at this level of changes.
The following figure (Figure 4.) gives an overview about 
the release rates of some selected (based on the stability data) 
products from the different types. No significant differences in 
release rates were found in case of the following compositions: 
organogel containing 25.0 w/w% gelling agent (DSOG 25), the 
w/o cream with 45.0 w/w% internal water content (DSVO45) 
and the hydrogel product containig 1.0 w/w% polymer content 
(DSHG1). 
The release rate from the emulgel with 45.0 w/w polymer 
containing water phase showed a slightly higher released acive 
agent amount after 6 hours, but still not evaluated as significant 
change. These compositions therefore, can be predicted to be 
equivalent in their „in vivo” performance; in spite of the fact, 
that they vary in composition and product type.  
Significant difference from these products was found in 
case of the 75.0 w/w % external aqueous phase containing o/w 
cream (DSOV75).
Figure 5. shows the difference between the release rates of 
the primary w/o emulsion and a w/o/w product; after adding 
Tab. 1. Products containing 1 % diclofenac sodium
Tab. 2. Products containing 1 w/w% ketamine HCl 
dosage form composition marked as:
hydrogel polymer (Carbomer 934 P)  
content (w/w%):
(1) 0.8 (2) 0.9 (3) 1.0 
DSHG 0.8
DSHG 0.9
DSHG 1.0
organogel gelling agent (sorbitan monopalmitate) 
content (w/w%):
(4) 25.0 (5) 30.0 (6) 35.0
DSOG 25
DSOG 30
DSOG 35
o/w emulgel polymer (Pemulen TR-2) containing 
aqueous phase (w/w%): 
(7) 40.0 (8) 45.0 (9) 50.0
DSGE 40
DSGE 45
DSGE 50
o/w cream aqueous phase (w/w%):
(10) 65.0 (11) 70.0 (12) 75.0 
DSOV 65
DSOV 70
DSOV 75
w/o cream aqueous phase (w/w%):
(13) 40.0 (14) 45.0 (15) 50.0
DSVO 40
DSVO 45
DSVO 50
dosage form composition marked as:
w/o  
emulsion
(16) aqueous phase  
(w/w%): 75.0
w/o
w/o/w  
emulsion
(17) primary ((16)w/o emulsion) phase 
(w/w%):40.0
w/o/w
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the external aqueous phase to the primary (w/o) one. The same 
amount of the active agent was incorporated into the aqueous 
phase of the primary; and in case of the inner and external 
water phases of the multiple emulsion. 75.0 % of the drug dis-
solved in the multiple emulsion released during 5 hours; while 
37% from the primary simple one. The advantage of multiple 
emulsions for achieving faster drug release from its external 
phase, followed by a slower drug dissolution from the inner 
phases – could be detected.
5 Conclusions
Dissolution testing has an increasing role in case of all do-
sage forms in pharmaceutical dosage form design and develop-
ment. Its applicability can be extended to cosmetic products as 
well; as alternative method instead of animal testing. 
Different levels of product composition changes and “simi-
larity” in case of different products can be detected only after a 
careful validation of the drug release measurement with Franz 
vertical diffusion cell system.
Fig. 2. Drug release from hydrogels in case of different polymer content
Fig. 4. Drug release from different dosage forms Fig. 5. Drug release from emulsions (primary w/o and the final w/o/w)
Fig. 3. Drug release from w/o creams with different aqueous phase ratio
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